Evidence map›Paper›PMID 36333165›Full record

ArticleHuman immunology2023

TNFRSF13B in B cell responses to organ transplantation.

Marilia Cascalho, Jeffrey L Platt

Open access · hybridAbstract read
In one paragraph

Article in Human immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Single-cell dissection of pleural and systemic immunity uncovers pathogen-specific immune reprogramming in tuberculosis versus lung adenocarcinoma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marilia CascalhoDepartment of Surgery and Department of Microbiology & Immunology, University of Michigan, Ann Arbor, MI, United States. Electronic address: marilia@umich.edu.
Jeffrey L PlattDepartment of Surgery and Department of Microbiology & Immunology, University of Michigan, Ann Arbor, MI, United States. Electronic address: plattJl@umich.edu.
University of Michigan–Ann Arbor · US

Funding

Donor-specific B cells in Transplantation.R01AI151588 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASCALHO, MARILIA ISABEL, PLATT, JEFFREY L · 2020 to 2025
$2.7M
TNRSF13B polymorphisms and the control of innate B cell responses – a double edged swordR21AI159219 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASCALHO, MARILIA ISABEL, PLATT, JEFFREY L · 2021 to 2022
$429k
NIAID NIH HHS R01 AI151588NIAID NIH HHS R21 AI159219
6 · The paper itself

Abstract

Antibodies directed against organ transplants are thought to pose the most vexing hurdle to enduring function and survival of the transplants, particularly organ xenotransplants, and accordingly basic and clinical investigation has focused on elucidating the specificity and pathogenicity of graft-specific antibodies. While much has been learned about these matters, far less is known about the B cells producing graft-specific antibodies and why these antibodies appear to injure some grafts but not others. With the goal of addressing those questions, we have investigated the properties of tumor necrosis factor receptor super family-13B (TNFRSF13B), which regulates various aspects of B cell responses. A full understanding of the functions of TNFRSF13B however is hindered by extreme polymorphism and by diversity of interactions of the protein. Nevertheless, TNFRSF13B variants have been found to exert distinct impact on natural and elicited antibody responses and host defense and mutations of TNFRSF13B have been found to influence the propensity for development of antibody-mediated rejection of organ transplants. Because B cell responses potentially limit application of xenotransplantation, understanding how TNFRSF13B diversity and TNFRSF13B variants govern immunity in xenotransplantation could inspire development of novel therapeutics that could in turn accelerate clinical implementation of xenotransplantation.

Indexed as

B-LymphocytesOrgan TransplantationAntibodiesGraft RejectionHumansMutationPolymorphism, GeneticTransmembrane Activator and CAML Interactor ProteinTransplantation, HeterologousAntibodiesTNFRSF13B protein, humanTransmembrane Activator and CAML Interactor ProteinAntibody-mediated rejectionAPRILB cellsComplementNatural antibodiesTACITACI-IgT cell-dependent responseTNFRSF13BTransplantation immunityXenotransplantation

Identifiers

PMID36333165
PMCPMC10429825
OpenAlexW4308035122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.